Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIAL: DCT vs Hybrid vs Conventional in T2DM with Toujeo
NCT05780151Phase 4Completed
- Start
- Jul 2023
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (3 arms). Primary endpoints: Enrolment rates at 32 weeks, Retention rates at 6 months and 8 more. Started Jul 2023; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05780151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780151.